GPP
DRUG

Great Point Partners’s Bright Minds Biosciences DRUG Stock Holding History

Great Point Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.69M Sell
109,603
-110,397
-50% -$8.67M 1.45% 24
2026
Q1 		$16.1M Buy
+220,000
New +$17.7M 3.69% 9

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Great Point Partners's DRUG Position: Q2 2026 in Review

Great Point Partners reduced its Bright Minds Biosciences (DRUG) stake by 50% in Q2 2026, selling an estimated $8.67M and leaving 109,603 shares worth $7.69M. The position accounts for 1.45% of the portfolio, ranked #24.

Great Point Partners first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. The position peaked at $16.1M in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Great Point Partners held 109,603 shares of Bright Minds Biosciences worth $7.69M as of Q2 2026.
  • Great Point Partners sold 110,397 Bright Minds Biosciences shares in Q2 2026, an estimated $8.67M.
  • Bright Minds Biosciences made up 1.45% of Great Point Partners's portfolio in Q2 2026, its #24 holding.
  • Great Point Partners first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Great Point Partners's Bright Minds Biosciences position peaked at $16.1M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.